A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection

NCT07142811 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Viral Hepatitis

Interventions

DRUG: Tobevibart
DRUG: Elebsiran
DRUG: Bulevirtide

Sponsor

Vir Biotechnology, Inc.